YU10603A - Upotreba metalnih kompleksa koji sadrže perfluoroalkile kao kontrastnog sredstva u mr vizualizaciji za predstavljanje plaka, tumora i nekroza - Google Patents

Upotreba metalnih kompleksa koji sadrže perfluoroalkile kao kontrastnog sredstva u mr vizualizaciji za predstavljanje plaka, tumora i nekroza

Info

Publication number
YU10603A
YU10603A YU10603A YUP10603A YU10603A YU 10603 A YU10603 A YU 10603A YU 10603 A YU10603 A YU 10603A YU P10603 A YUP10603 A YU P10603A YU 10603 A YU10603 A YU 10603A
Authority
YU
Yugoslavia
Prior art keywords
representation
imaging
metal complexes
contrast agents
complexes containing
Prior art date
Application number
YU10603A
Other languages
English (en)
Inventor
Johannes Platzek
Peter Mareski
Ulrich Niedballa
Bernd Raduchel
Hanns-Joachim Weinmann
Bernd Misselwitz
Original Assignee
Schering Aktiengesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE10040380A external-priority patent/DE10040380B4/de
Application filed by Schering Aktiengesellschaft filed Critical Schering Aktiengesellschaft
Publication of YU10603A publication Critical patent/YU10603A/sh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1806—Suspensions, emulsions, colloids, dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/085—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier conjugated systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/101—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
    • A61K49/103—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being acyclic, e.g. DTPA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/101—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
    • A61K49/106—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being cyclic, e.g. DOTA

Landscapes

  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Radiology & Medical Imaging (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Pronalazak se odnosi na primenu metalnih kompleksa koji sadrže perfluoralkile, koji imaju kritičnu koncentraciju gradnje micela <10-3 hidrodinamički prečnik micela (2RH)>1 nm i protonen relaxivity u plazmi (RI)>10 1/mmols kao kontrastnog sredstva u MR-vizuelizaciji za predstavljanje plaka, limfnih čvorova infarktog i nekrotičnog tkiva kao i za nezavisno predstavljanje nekrotičnog tkiva i tumorskog tkiva.[The invention relates to the use of metal complexes containing perfluoroalkyl, comprising a critical micelle formation concentration <10-3 mol/l, a hydrodynamic micelle dynameter of (2Rh) >1 nm and a proton relaxivity in plasma (R1) > 101/mmol.s, as contrast agents in MR imaging for the representation of plague, lymph node, infracted and necrotic tissue and for independent representation of necrotic tissue and tumoural tissue.
YU10603A 2000-08-11 2001-07-23 Upotreba metalnih kompleksa koji sadrže perfluoroalkile kao kontrastnog sredstva u mr vizualizaciji za predstavljanje plaka, tumora i nekroza YU10603A (sh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10040380A DE10040380B4 (de) 2000-08-11 2000-08-11 Verwendung von perfluoralkylhaltigen Metallkomplexen als Kontrastmittel im MR-Imaging zur Darstellung von Plaques

Publications (1)

Publication Number Publication Date
YU10603A true YU10603A (sh) 2006-05-25

Family

ID=7652860

Family Applications (1)

Application Number Title Priority Date Filing Date
YU10603A YU10603A (sh) 2000-08-11 2001-07-23 Upotreba metalnih kompleksa koji sadrže perfluoroalkile kao kontrastnog sredstva u mr vizualizaciji za predstavljanje plaka, tumora i nekroza

Country Status (26)

Country Link
EP (1) EP1307236A2 (sh)
JP (1) JP2004506025A (sh)
KR (1) KR20030022387A (sh)
CN (1) CN1469757A (sh)
AR (1) AR034139A1 (sh)
AU (2) AU7754901A (sh)
BG (1) BG107542A (sh)
BR (1) BR0113188A (sh)
CA (1) CA2419223A1 (sh)
CZ (1) CZ2003392A3 (sh)
DE (1) DE10066210B4 (sh)
EE (1) EE200300061A (sh)
HR (1) HRP20030173A2 (sh)
HU (1) HUP0300736A3 (sh)
IL (1) IL154385A0 (sh)
MX (1) MXPA03001287A (sh)
NO (1) NO20030604L (sh)
NZ (1) NZ523932A (sh)
PL (1) PL365596A1 (sh)
RU (1) RU2290206C2 (sh)
SK (1) SK1572003A3 (sh)
TW (1) TWI296931B (sh)
UA (1) UA82642C2 (sh)
WO (1) WO2002013874A2 (sh)
YU (1) YU10603A (sh)
ZA (1) ZA200301949B (sh)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7344704B2 (en) 2002-07-10 2008-03-18 Schering Ag Use of perfluoroalkyl-containing metal complexes as contrast media in MR-imaging for visualization of intravascular thrombi
DE10231799B4 (de) * 2002-07-10 2006-10-05 Schering Ag Verwendung von perfluoralkylhaltigen Metallkomplexen als Kontrastmittel im MR-Imaging zur Darstellung von Intravasalen Thromben
DE102005008309A1 (de) * 2005-02-17 2006-08-24 Schering Ag Pharmazeutische Mittel enthaltend fluoralkylhaltige Metallkomplexe und Epothilone
DE102006021495A1 (de) * 2006-05-09 2007-11-15 Bayer Schering Pharma Ag Verwendung von perfluoralkylhaltigen Metallkomplexen als Kontrastmittel zur Diagnose der Alzheimer Krankheit
US7887835B2 (en) * 2006-09-19 2011-02-15 Fujifilm Corporation Compound comprising a fluorine-substituted alkyl group and a liposome contrast medium comprising the compound
DE102006049821A1 (de) 2006-10-18 2008-04-24 Bayer Schering Pharma Aktiengesellschaft Metallchelate mit perfluoriertem PEG-Rest, Verfahren zu deren Herstellung, sowie deren Verwendung
DE102007015598A1 (de) * 2007-03-29 2008-10-02 Heinrich-Heine-Universität Düsseldorf Verwendung von fluorhaltigen Verbindungen zu Diagnosezwecken mit Hilfe bildgebender Verfahren
JP2011190183A (ja) * 2010-03-11 2011-09-29 Noguchi Institute フルオラス化糖結合型クラウンエーテル誘導体
US9976072B2 (en) * 2014-03-26 2018-05-22 Chevron U.S.A. Inc. Multicarboxylate compositions and method of making the same
EP3101012A1 (en) 2015-06-04 2016-12-07 Bayer Pharma Aktiengesellschaft New gadolinium chelate compounds for use in magnetic resonance imaging
CN115594579A (zh) 2016-09-14 2023-01-13 大金工业株式会社（Jp） 含支链含氟化合物
CA3044877A1 (en) 2016-11-28 2018-05-31 Bayer Pharma Aktiengesellschaft High relaxivity gadolinium chelate compounds for use in magnetic resonance imaging
JOP20210114A1 (ar) 2018-11-23 2023-01-30 Bayer Ag تركيبة وسط تباين وعملية لتحضيرها
CN109867635A (zh) * 2019-02-14 2019-06-11 华东师范大学 一种t1型胶束磁共振成像造影剂及其制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19603033A1 (de) * 1996-01-19 1997-07-24 Schering Ag Perfluoralkylhaltige Metallkomplexe, Verfahren zu deren Herstellung und ihre Verwendung in der NMR-Diagnostik
JPH10112939A (ja) * 1996-10-07 1998-04-28 Nec Corp 電源切替回路
DE19729013A1 (de) * 1997-07-03 1999-02-04 Schering Ag Oligomere, perfluoralkylhaltige Verbindungen, Verfahren zu deren Herstellung und ihre Verwendung in der NMR-Diagnostik
US6019959A (en) * 1997-07-31 2000-02-01 Schering Aktiengesellschaft Oligomeric compounds that contain perfluoroalkyl, process for their production, and their use in NMR diagnosis

Also Published As

Publication number Publication date
JP2004506025A (ja) 2004-02-26
EP1307236A2 (de) 2003-05-07
DE10066210B4 (de) 2008-02-28
HUP0300736A2 (hu) 2003-09-29
UA82642C2 (uk) 2008-05-12
MXPA03001287A (es) 2003-10-06
TWI296931B (en) 2008-05-21
AU7754901A (en) 2002-02-25
NO20030604L (no) 2003-04-11
AR034139A1 (es) 2004-02-04
CZ2003392A3 (cs) 2003-09-17
EE200300061A (et) 2004-12-15
PL365596A1 (en) 2005-01-10
WO2002013874A8 (de) 2002-06-13
RU2290206C2 (ru) 2006-12-27
AU2001277549B2 (en) 2007-02-08
NO20030604D0 (no) 2003-02-07
WO2002013874A2 (de) 2002-02-21
HUP0300736A3 (en) 2010-01-28
KR20030022387A (ko) 2003-03-15
IL154385A0 (en) 2003-09-17
NZ523932A (en) 2007-07-27
HRP20030173A2 (en) 2005-04-30
SK1572003A3 (en) 2003-10-07
CA2419223A1 (en) 2003-02-11
CN1469757A (zh) 2004-01-21
ZA200301949B (en) 2004-12-14
BR0113188A (pt) 2003-06-24
BG107542A (bg) 2003-09-30

Similar Documents

Publication Publication Date Title
YU10603A (sh) Upotreba metalnih kompleksa koji sadrže perfluoroalkile kao kontrastnog sredstva u mr vizualizaciji za predstavljanje plaka, tumora i nekroza
NO20050679L (no) Anvendelse av metallkomplekser inneholdende perfluoralkyl som kontrastmidler i magnetisk resonansbildedannelse for a fremvise intravaskulaere tromber
Troughton et al. Synthesis and evaluation of a high relaxivity manganese (II)-based MRI contrast agent
Herborn et al. Intraindividual comparison of gadopentetate dimeglumine, gadobenate dimeglumine, and gadobutrol for pelvic 3D magnetic resonance angiography
WO2000030688A3 (en) Amphipatic polycarboxylic chelates and complexes with paramagnetic metals as mri contrast agents
CA2268324A1 (en) Administrable compositions and methods for magnetic resonance imaging
DE60131257D1 (de) Diffusionsbildgebung von gewebe
IS2127B (is) Málmsamstæður sem innihalda Perflúoróalkýl og notkun þeirra við segulsneiðmyndunar-greiningar
TW200711664A (en) Compositions containing magnetic iron oxide particles, and use of said compositions in imaging methods
DK0560910T3 (da) I molekylsigte indesluttet paramagnetisk ion for diagnose
Thomann et al. Pulsed EPR studies of mixed valent [Fe (II) Fe (III)] forms of hemerythrin and methane monooxygenase: evidence for a hydroxide bridge
AU2001277549A1 (en) Use of metal complexes containing perfluoroalkyl as contrast agents in mr-imaging for the representation of plaques, tumours and necroses
NO933421L (no) Konstrastmiddel
EP0861066B1 (en) Improved pseudocatalase composition
WO2010128787A3 (ko) 가돌리늄 착물, 그 제조방법, 및 그것을 포함하는 ｍｒｉ 조영제
AU3221195A (en) Macrocyclic chelants, their chelates and uses thereof in the diagnostic field
Cornily et al. Evaluation of neovessels in atherosclerotic plaques of rabbits using an albumin‐binding intravascular contrast agent and MRI
Neya et al. Proton NMR study of the myoglobin reconstituted with meso-tetra (n-propyl) hemin
Laurent et al. Noncovalent Binding of Some New Lipophilic Gadolinium DTPA Complexes to Human Serum Albumin. A Structure–Affinity Relationship
ATE211727T1 (de) 5-hydroxymethyl-2-aminotetraline als cardiovasculäre mittel
WO2003001218A3 (en) Macromolecular imaging agents for liver imaging
Erstad et al. A novel manganese MRI contrast agent (PyC3A) for the evaluation of hepatic neoplasms
WO2000024429A3 (en) Compound